FOR HEART FAILURE PATIENTS WITH PRESERVED SYSTOLIC FUNCTION
TOPCAT is a multi-center,
international, randomized, double blind placebo-controlled
trial of the aldosterone antagonist, spironolactone, in 3,445 adult subjects
with heart failure and left ventricular ejection fraction
of at least 45%, recruited internationally from over 200 clinical
centers in the US, Canada, Russia, Republic of Georgia, Argentina,
The trial is sponsored
by the National Heart, Lung, and Blood Institute of the National
Institutes of Health. New England Research Institutes, Inc.
(NERI) and The Brigham & Women’s Hospital (BWH)
serve as the Clinical Trial Coordinating Center (CTCC) for
Enrollment started in August 2006 and recently ended on January 31, 2012.